At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Efavirenz +1 moredrug
Likely dose
Efavirenz 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial Comparing Efavirenz With Rilpivirine on Changes in Endothelial Function, Inflammatory Markers, and Oxidative Stress in HIV-uninfected Healthy Volunteers
In Brief
A Phase 4 clinical trial evaluating Efavirenz and Rilpivirine for Cardiovascular Disease. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the cardiovascular profiles of efavirenz and rilpivirine, which are two drugs used to treat HIV infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease
CountriesUnited States
CollaboratorsJanssen Services, LLC
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartJul 2012
Primary CompletionMay 2014
Study CompletionNov 2014
TodayJul 2026
First PostedApr 25, 2012
Enrollment StartJul 1, 2012
Primary CompletionMay 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.2 years ago
Interventions
Efavirenzdrug
600mg orally every evening
Rilpivirinedrug
25mg orally once daily